New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AZN;MYL From The Last 14 Days
Check below for free stories on AZN;MYL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 19, 2014
18:50 EDTMYLMylan says Teva denied injunction seeking to prevent launch of generic Copaxone
Subscribe for More Information
11:12 EDTAZNLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 17, 2014
04:22 EDTMYLMylan (MYL) implied volatility of 45 at upper end of index mean range
April 16, 2014
16:16 EDTMYLMylan launches first generic Ortho Evra patch
Subscribe for More Information
April 15, 2014
10:21 EDTMYLMylan announces settlement agreement for first-to-file Generess
Subscribe for More Information
10:10 EDTMYLMylan launches generic Lunesta tablets
Subscribe for More Information
08:19 EDTAZNLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:07 EDTMYLActavis announces agreement related to Generess FE patent challenge litigation
Actavis (ACT) announced that it has entered into an agreement with Mylan (MYL) and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess. Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess® FE under its pending Abbreviated New Drug Application beginning on April 1, 2015. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Other terms of the settlement were not disclosed. Actavis remains in litigation with Lupin Ltd in connection with Lupin's pending ANDA for a generic version of Generess.
08:06 EDTMYLProsonix, Mylan enter licensing deal for generic version of Flixotide, Flovent
Subscribe for More Information
06:32 EDTAZNPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 11, 2014
11:50 EDTMYLStocks with call strike movement; TNA MYL
Subscribe for More Information
10:30 EDTMYLActavis and Mylan shares recommended at Bernstein
07:31 EDTMYLMylan confirms judge enforces agreement with Endo regarding generic Frova
Subscribe for More Information
April 9, 2014
05:57 EDTMYLMylan implied volatility of 47 at upper end of index mean range
April 8, 2014
11:03 EDTAZNPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
07:56 EDTMYLMylan volatility elevated at 42
Subscribe for More Information
April 7, 2014
16:34 EDTAZNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
07:27 EDTAZNAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
05:48 EDTAZNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use